ArticleContemporary clinical trials communications2020
Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials.
Article in Contemporary clinical trials communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Recruitment and retention strategies for improving representation in clinical research: A meta-synthesis.PloS one · 2025Pooled it
- REPRESENT recommendations: improving inclusion and trust in cancer early detection research.British journal of cancer · 2023Pooled it
- Exploring Racial Disparities in Awareness and Perceptions of Oncology Clinical Trials: Cross-Sectional Analysis of Baseline Data From the mychoice Study.JMIR cancer · 2024Trial
- Faith, Culture, and Cancer: A Qualitative Study Exploring Muslim Women's Perspectives on Clinical Trials in the United Kingdom.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Outreach to Native Hawaiian and Pacific Islander communities to increase breast cancer screening and clinical trial awareness.BMC cancer · 2026Article
- Strategies for optimizing clinical trial recruitment: perspectives among patients with breast cancer.Cancer causes & control : CCC · 2026Article
- Mixed-Methods Approach: Impact of Clinical Consenter Diversity on Clinical Trials Enrollment.Cancers · 2025Article
- How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- Ethnic Minority Participation in Clinical Trials from Latin America and the Caribbean: A Scoping Review.Journal of immigrant and minority health · 2024Article
- Data-driven strategies for increasing patient diversity in Bristol Myers Squibb-sponsored US oncology clinical trials.Clinical trials (London, England) · 2023Article
- Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment.JCO oncology practice · 2023Article
- Reimagining diversity in multiple myeloma clinical trials.Hematological oncology · 2022Article
- Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.British journal of clinical pharmacology · 2022Review
- Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603).JCO clinical cancer informatics · 2021Article
- Development of an Actionable Framework to Address Cancer Care Disparities in Medically Underserved Populations in the United States: Expert Roundtable Recommendations.JCO oncology practice · 2021Article
- Enhancing African American Participation in Biospecimens: A Case in Point for Pancreatic Cancer.Cancer health disparities · 2020Article
- Guidelines for Evaluating the Feasibility of Recruitment in Pilot Studies of Diverse Populations: An Overlooked but Important Component.Ethnicity & disease · 2020Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Funding
Abstract
backgroundStudy populations in clinical research must reflect US changing demographics, especially with the rise of precision medicine. However, racial and ethnic minority groups (REMGs) have low rates of participation in cancer clinical trials.
methodsCriteria were developed to identify cancer centers able to accrue a higher than average proportion of REMGs into clinical trials. Comprehensive interviews were conducted with leaders of these cancer centers to identify operational strategies contributing to enhanced accrual of REMGs.
resultsEight US cancer centers reported a REMG accrual rate range in cancer research between 10 and 50% in a 12-month reporting period and met other criteria for inclusion. Fourteen leaders participated in this assessment. Key findings were that centers: had a metric collection and reporting approach; routinely captured race and ethnicity data within databases accessible to research staff; had operational standards to support access and inclusion; developed practices to facilitate sustained patient participation during clinical trials; had strategies to decrease recruitment time and optimize clinical study design; and identified low-resource strategies for REMG accrual. There was also a clear commitment to establish processes that support the patient's provider as the key influencer of patient recruitment into clinical trials.
conclusionWe have identified operational practices that facilitate increased inclusion of REMGs in cancer trials. In order to establish a sustainable cancer center inclusion research strategy, it is valuable to include an operational framework that is informed by leading US cancer centers of excellence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.